Artificial intelligence identifies anti-aging drug candidates targeting ‘zombie’ cells

Integrated Biosciences’ new platform has potential to fuel advances in senolytic anti-aging compounds and longevity research

AI-driven platform built on work pioneered at MIT identifies three candidates with comparable efficacy and superior medicinal chemistry relative to current investigational compounds

Treatment of aged mice reduced number of senescent ‘zombie’ cells and lowered expression of senescence-associated genes

SAN CARLOS, Calif.--(BUSINESS WIRE)--Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, in collaboration with researchers at the Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard, today announced results demonstrating the power of artificial intelligence (AI) to discover novel senolytic compounds, a class of small molecules under intense study for their ability to suppress age-related processes such as fibrosis, inflammation and cancer. A new publication authored by company founders in Nature Aging, “Discovering small-molecule senolytics with deep neural networks,” describes the AI-guided screening of more than 800,000 compounds to reveal three drug candidates with comparable efficacy and superior medicinal chemistry properties than those of senolytics currently under investigation.

“This research result is a significant milestone for both longevity research and the application of artificial intelligence to drug discovery,” said Felix Wong, Ph.D., co-founder of Integrated Biosciences and first author of the publication. “These data demonstrate that we can explore chemical space in silico and emerge with multiple candidate anti-aging compounds that are more likely to succeed in the clinic, compared to even the most promising examples of their kind being studied today.”

Senolytics are compounds that selectively induce apoptosis, or programmed cell death, in senescent cells that are no longer dividing. A hallmark of aging, senescent cells have been implicated in a broad spectrum of age-related diseases and conditions including cancer, diabetes, cardiovascular disease, and Alzheimer’s disease. Despite promising clinical results, most senolytic compounds identified to date have been hampered by poor bioavailability and adverse side effects. Integrated Biosciences was founded in 2022 to overcome these obstacles, target other neglected hallmarks of aging, and advance anti-aging drug development more generally using artificial intelligence, synthetic biology and other next-generation tools.

“One of the most promising routes to treat age-related diseases is to identify therapeutic interventions that selectively remove these cells from the body similarly to how antibiotics kill bacteria without harming host cells. The compounds we discovered display high selectivity, as well as the favorable medicinal chemistry properties needed to yield a successful drug,” said Satotaka Omori, Ph.D., Head of Aging Biology at Integrated Biosciences and joint first author of the publication. “We believe that the compounds discovered using our platform will have improved prospects in clinical trials and will eventually help restore health to aging individuals.”

In their new study, Integrated Biosciences researchers trained deep neural networks on experimentally generated data to predict the senolytic activity of any molecule. Using this AI model, they discovered three highly selective and potent senolytic compounds from a chemical space of over 800,000 molecules. All three displayed chemical properties suggestive of high oral bioavailability and were found to have favorable toxicity profiles in hemolysis and genotoxicity tests. Structural and biochemical analyses indicate that all three compounds bind Bcl-2, a protein that regulates apoptosis and is also a chemotherapy target. Experiments testing one of the compounds in 80-week-old mice, roughly corresponding to 80-year-old humans, found that it cleared senescent cells and reduced expression of senescence-associated genes in the kidneys.

“This work illustrates how AI can be used to bring medicine a step closer to therapies that address aging, one of the fundamental challenges in biology,” said James J. Collins, Ph.D., Termeer Professor of Medical Engineering and Science at MIT and founding chair of the Integrated Biosciences Scientific Advisory Board. “Integrated Biosciences is building on the basic research that my academic lab has done for the last decade or so, showing that we can target cellular stress responses using systems and synthetic biology. This experimental tour de force and the stellar platform that produced it make this work stand out in the field of drug discovery and will drive substantial progress in longevity research.”

Dr. Collins, who is senior author on the Nature Aging paper, led the team which discovered the first antibiotic identified by machine learning in 2020.

About Integrated Biosciences

Integrated Biosciences is a seed-stage biotechnology company that has developed proprietary synthetic biology and AI platforms to target age-related cellular stress responses. Integrated Biosciences was founded by MIT-, Harvard- and Princeton-trained scientists Felix Wong, Ph.D., and Max Wilson, Ph.D., in 2022. Its scientific advisors include James J. Collins, Ph.D., one of the founders of the field of synthetic biology and Termeer Professor of Medical Engineering and Science at MIT, and Sir David W. C. MacMillan Ph.D., 2021 winner of the Nobel Prize in Chemistry and James S. McDonnell Distinguished University Professor of Chemistry at Princeton. Its investors include Root Ventures, Mission BioCapital, Conscience VC, Reinforced Ventures and Polymath Capital. Integrated Biosciences is based in San Carlos, California.

Media:
Kit Rodophele
Ten Bridge Communications
617-999-9620
krodophele@tenbridgecommunications.com